ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2597

Fine Specificity of Anti-Citrullinated Peptide Antibodies Is Associated with Left Ventricular Mass Index in Rheumatoid Arthritis Patients without Cardiovascular Disease

Laura Geraldino-Pardilla1, Jon T. Giles2, Jeremy Sokolove3, Afshin Zartoshti4, WH Robinson5 and Joan M. Bathon6, 1Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, 2Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, 3Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, 4Rheumatology, Columbia University Medical Center, NY, NY, 5Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 6Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: ACPA, heart disease and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Heart failure (HF) is a leading
cause of excess deaths in RA. We previously found an association between left
ventricular mass index (LVMI) and anti-citrullinated peptide antibodies (ACPA)
in rheumatoid arthritis (RA) patients without CVD. Our objective was to validate
these findings in a different RA cohort of patients without CVD.

Methods:  Seventy-four patients without
known CVD from underwent 3D Echocardiography and concurrent serum testing of a
panel of 30 specific ACPAs using a custom Bio-Plex bead array. With a high ACPA
level defined as ≥ 75th percentile, a cross-sectional analysis
of the association of specific ACPAs and LVMI was performed. Traditional CVD
risk factors and RA characteristics were adjusted for.

Results: The mean age of the patients was 54
years (±13), with 85% being females and 36% self-identified as non-Hispanic White.
The median disease duration was 7 years (IQR: 3-17), 67% had a positive
anti-CCP antibody, and the mean current RA disease activity, based on the DAS28-CRP,
was 3.9 (IQR: 2.9-4.5). Forty percent were hypertensive, 11% had diabetes, and
7% were current smokers. Except for a higher proportion of patients with
rheumatoid factor level> 40units, no differences were seen between those
with high vs. low anti-CCP titers. High anti-citrullinated fibrinogen, anti-citrullinated
vimentin, and anti-citrullinated fibronectin antibody levels were associated
with a higher LVMI compared to low levels of these antibodies (68 vs. 58 g/m2,
p=0.02; 67 vs. 58 g/m2, p=0.003; and 69 vs. 57 g/m2,
p=0.004; respectively).  These associations remained significant in the
adjusted analyses (69 vs. 58 g/m2, p=0.04; 67 vs. 58 g/m2,
p=0.004; 72 vs. 57 g/m2, p=0.009; respectively) (figure 1).

Conclusion: In concordance with our previous findings, specific ACPAs were associated with a
higher LVMI in RA patients without CVD. This independent association suggests a
link between autoimmunity and cardiac structure in RA.

Figure 1. Association of ACPA status with Left Ventricular mass
index.

Figure 1. High anti-citrullinated-vimentin, anti-citrullinated-fibrinogen,
and anti-citrullinated fibronectin antibody levels were associated with higher
LVMI. *Adjusted for hypertension.

 


Disclosure: L. Geraldino-Pardilla, None; J. T. Giles, None; J. Sokolove, None; A. Zartoshti, None; W. Robinson, None; J. M. Bathon, None.

To cite this abstract in AMA style:

Geraldino-Pardilla L, Giles JT, Sokolove J, Zartoshti A, Robinson W, Bathon JM. Fine Specificity of Anti-Citrullinated Peptide Antibodies Is Associated with Left Ventricular Mass Index in Rheumatoid Arthritis Patients without Cardiovascular Disease [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/fine-specificity-of-anti-citrullinated-peptide-antibodies-is-associated-with-left-ventricular-mass-index-in-rheumatoid-arthritis-patients-without-cardiovascular-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fine-specificity-of-anti-citrullinated-peptide-antibodies-is-associated-with-left-ventricular-mass-index-in-rheumatoid-arthritis-patients-without-cardiovascular-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology